- $1.95bn
- $2.59bn
- $902.25m
- 86
- 38
- 55
- 61
2019 January 31st | R2020 January 31st | R2021 January 31st | 2022 January 31st | 2023 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,230 | 847 | 830 | 875 | 902 |
Cost of Revenue | |||||
Gross Profit | 781 | 542 | 543 | 576 | 607 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,116 | 848 | 773 | 830 | 845 |
Operating Profit | 114 | -1.97 | 57.3 | 44.4 | 57.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 77.8 | -39.6 | -41.7 | 39.5 | 54.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | 70.2 | -46.5 | -48.6 | 15.7 | 15.7 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 66 | 28.7 | -7.27 | 14.4 | 14.9 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 66 | 28.7 | -14.9 | -4.51 | -5.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.21 | -0.659 | -0.865 | -0.007 | 0.075 |